SDGR Schrodinger Inc.

102.94
-1.56  -1%
Previous Close 104.5
Open 104
52 Week Low 27.04
52 Week High 117
Market Cap $7,153,004,236
Shares 69,487,121
Float 30,097,977
Enterprise Value $6,978,331,862
Volume 1,304,907
Av. Daily Volume 841,154
Stock charts supplied by TradingView

Latest News

  1. Schrödinger, Inc. (NASDAQ:SDGR) today announced it has expanded its collaboration with Google Cloud to further increase the speed and capacity of its physics-based computational platform for drug discovery and materials science. This new five-year agreement replaces the previous three-year commitment entered into in November 2019.

    This expanded partnership will provide Schrödinger with hundreds of millions of graphics processing unit (GPU) hours, effectively tripling Schrödinger's previous throughput, and pushing the capacity to the equivalent of the world's most powerful supercomputers. Schrödinger aims to further accelerate drug discovery and materials design through the application of its large-scale physics-based and machine learning methods…

    Schrödinger, Inc. (NASDAQ:SDGR) today announced it has expanded its collaboration with Google Cloud to further increase the speed and capacity of its physics-based computational platform for drug discovery and materials science. This new five-year agreement replaces the previous three-year commitment entered into in November 2019.

    This expanded partnership will provide Schrödinger with hundreds of millions of graphics processing unit (GPU) hours, effectively tripling Schrödinger's previous throughput, and pushing the capacity to the equivalent of the world's most powerful supercomputers. Schrödinger aims to further accelerate drug discovery and materials design through the application of its large-scale physics-based and machine learning methods.

    "This is a pivotal moment for Schrödinger as we seek to strengthen our leadership position in physics-based approaches to molecular modeling. Our initial work last year with Google Cloud demonstrated our ability to apply large-scale computation to significantly accelerate drug discovery programs," stated Shane Brauner, Schrödinger's Chief Information Officer. "Our increased commitment provides unmatched computational scale to enable rapid, efficient and accurate exploration of chemical space, with a goal of advancing development programs for our pipeline."

    "We are thrilled to provide best-in-class resources to enable research and the development of life-saving drugs by life science organizations to rapidly advance the next generation of therapies that will transform the lives of patients and their families," said Joe Miles, Managing Director of Google Cloud Healthcare and Life Sciences. "It has been a pleasure working closely with the Schrödinger team over the last year, and we look forward to continuing a productive partnership."

    For further information about Schrödinger's work with Google Cloud visit the case study or video online.

    About Schrödinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

    Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to, our expectations about the speed and capacity of our computational platform, and the potential of our platform to enable the discovery of high-quality, novel molecules for drug development and materials applications. Statements including words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "look forward," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including our reliance upon third-party providers of cloud-based infrastructure to host our software solutions, our reliance upon our third-party drug discovery collaborators, as well as the other risks and uncertainties identified under the caption "Risk Factors" and elsewhere in our Securities and Exchange Commission filings and reports, including the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2020, as well as future filings and reports by us. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.

    View Full Article Hide Full Article
  2. Schrödinger (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will provide a corporate overview at the SVB Leerink Partners 10th Annual Global Healthcare Conference. The presentation will take place virtually on Friday, February 26, 2021, at 3:00 p.m. ET.

    The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website and will be archived for approximately 14 days.

    About Schrödinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and…

    Schrödinger (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will provide a corporate overview at the SVB Leerink Partners 10th Annual Global Healthcare Conference. The presentation will take place virtually on Friday, February 26, 2021, at 3:00 p.m. ET.

    The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website and will be archived for approximately 14 days.

    About Schrödinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

    Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

    View Full Article Hide Full Article
  3. Schrödinger (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Thursday, March 4, 2021, at 8:30 a.m. ET to discuss fourth quarter and year-end 2020 financial results and provide a general business update.

    The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website. To participate in the live call, please dial (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and refer to conference ID 9686253. The archived webcast will be available on Schrödinger's website for approximately 90 days following the event.

    About Schrödinger
    Schrödinger is transforming…

    Schrödinger (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Thursday, March 4, 2021, at 8:30 a.m. ET to discuss fourth quarter and year-end 2020 financial results and provide a general business update.

    The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website. To participate in the live call, please dial (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and refer to conference ID 9686253. The archived webcast will be available on Schrödinger's website for approximately 90 days following the event.

    About Schrödinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

    Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

    View Full Article Hide Full Article
  4. SHANGHAI, Feb. 17, 2021 /PRNewswire/ -- Qiming's portfolio company New Horizon Health (SEHK:6606) officially listed on the Main Board of Hong Kong Stock Exchange (HKEx) today. This is the first listed Chinese cancer early screening company.

    The issue price is HK$26.66 per share; the stock opens at HK$76 per share, up 185.07%, with a market cap of HK$31.764 billion. New Horizon Health public offering shares were oversubscribed for 4,133 times with over HK$850 billion committed, making it the second most oversubscribed stock in the HKEx history.

    New Horizon Health's listing is the second IPO in our portfolio this year, and the 14th public listing in the past 13 months.

    Qiming started investing in New Horizon Health since its Series B round…

    SHANGHAI, Feb. 17, 2021 /PRNewswire/ -- Qiming's portfolio company New Horizon Health (SEHK:6606) officially listed on the Main Board of Hong Kong Stock Exchange (HKEx) today. This is the first listed Chinese cancer early screening company.

    The issue price is HK$26.66 per share; the stock opens at HK$76 per share, up 185.07%, with a market cap of HK$31.764 billion. New Horizon Health public offering shares were oversubscribed for 4,133 times with over HK$850 billion committed, making it the second most oversubscribed stock in the HKEx history.

    New Horizon Health's listing is the second IPO in our portfolio this year, and the 14th public listing in the past 13 months.

    Qiming started investing in New Horizon Health since its Series B round and followed on in all subsequent funding rounds. Qiming owns 8.59% of the company after the IPO.

    Founded in 2015, New Horizon Health is a cancer screening market leader, focusing on the design, development and commercialization of cancer screening tests. The company's vision is to prevent and cure cancer by screening and early detection. The company markets its tests through multiple channels, including hospitals, health checkup centers, insurance companies, pharmacy and online channels. The company has built a portfolio of 71 patents and patent applications globally.

    New Horizon Health's two approved cancer screening tests, Pupu Tube and ColoClear, address target populations with various risk levels.

    ColoClear, the company's proprietary, non-invasive, multi-target, FIT-DNA test, is the first and only molecular cancer screening test in China approved by NMPA. ColoClear targets a 120 million high-risk colorectal cancer population in China.

    Pupu Tube, the company's proprietary, non-invasive, stool-based FIT test, is the first self-conducted FIT screening product approved by NMPA. Pupu Tube targets a market of 633 million population (2019) recommended for colorectal cancer screening.

    Additionally, New Horizon Health has two late-stage product candidates for gastric and cervical cancer screening – UU Tube and CerviClear. UU Tube is a stool-based self-conducted screening test for gastric cancer. CerviClear is a non-invasive urine-based home-use screening test for cervical cancer.

    The company has built a proprietary and extensive database of Asian-specific colorectal cancer methylation profiles. The company's multi-parameter risk assessment algorithm is the first and only one for cancer screening in China.

    "New Horizon will address the big unmet cancer screening demands in China, and early detection will hopefully increase survival rate for cancer patients. The market size in China is expected to exceed 150 billion yuan. As an early market entrant, New Horizon Health has overcome regulatory and operational barriers with strong R&D and clinical capacities," said Nisa Leung, Managing Partner of Qiming Venture Partners.

    "Qiming is optimistic about the market, and we funded the company in multiple rounds. We expect to see the company contributing to lower cancer incidences, higher patients' survival rates, and potentially benefiting global users."

    About Qiming Venture Partners

    Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

    Currently Qiming Venture Partners manages nine US Dollar funds and six RMB funds with $5.9 billion in assets under management. Since our establishment, we have invested in outstanding companies in the TMT and healthcare industries at the early and growth stages.

    Since our debut, we have backed over 380 fast-growing and innovative companies. Over 130 companies are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange and Shenzhen Stock Exchange, or achieved exit through M&A and other means. There are also over 40 portfolio companies that have achieved unicorn status.

    Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688))), Venus MedTech (SEHK:2500), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), WeDoctor Group, and UBTech among many others.

    Cision View original content:http://www.prnewswire.com/news-releases/first-cancer-early-screening-company-listed-on-hkex-as-new-horizon-health-debuts-301230549.html

    SOURCE Qiming Venture Partners

    View Full Article Hide Full Article
  5. SHANGHAI and BEIJING and HONG KONG, Jan. 25, 2021 /PRNewswire/ -- Qiming Venture Partners ("Qiming") today announced the final close of our RMB Fund VI at RMB 2.852 billion.

    Currently, Qiming has $5.9 billion in assets under management, targeting early-and-growth-stage healthcare and TMT investments. Qiming raised our first RMB fund in 2010. For the past ten years, Qiming has demonstrated its ability to deliver consistent distinguished returns for LPs and has been well recognized by RMB fund investors.   

    Since our inception in 2006, Qiming has invested in more than 380 companies, among which over 40 achieved unicorn status. We have exited our investments in over 130 companies through IPO, M&A or other means. Notable exit deals include Xiaomi…

    SHANGHAI and BEIJING and HONG KONG, Jan. 25, 2021 /PRNewswire/ -- Qiming Venture Partners ("Qiming") today announced the final close of our RMB Fund VI at RMB 2.852 billion.

    Currently, Qiming has $5.9 billion in assets under management, targeting early-and-growth-stage healthcare and TMT investments. Qiming raised our first RMB fund in 2010. For the past ten years, Qiming has demonstrated its ability to deliver consistent distinguished returns for LPs and has been well recognized by RMB fund investors.   

    Since our inception in 2006, Qiming has invested in more than 380 companies, among which over 40 achieved unicorn status. We have exited our investments in over 130 companies through IPO, M&A or other means. Notable exit deals include Xiaomi, Gan & Lee Pharmaceuticals, Meituan, Bilibili, RoboRock, TigerMed, Zai Lab, CanSino Biologics Inc., Venus Medtech, APT Medical, and so forth.

    "Qiming has backed hundreds of brilliant entrepreneurs. We are pleased to see that those companies are committed to social good," said Duane Kuang, Founding Managing Partner of Qiming Venture Partners, "Qiming managed to close both RMB and USD funds in the past five months, showing that LPs are optimistic about our investment strategy to invest in China's innovative and developing science and technology, even during the challenging global COVID-19 epidemic as well as facing changing global environments." 

    In 2020, Qiming made over 70 investments; over 100 of our existing portfolio companies completed new financing rounds. As of today, we have had 13 successful public listings in our portfolio since 2020. Over 60 of our invested companies contributed to the fight against COVID-19 in China and for the global community. 

    "Innovation is the key for startups to break through and become leaders. In the past ten years, we have seen lots of Chinese entrepreneurs starting their business and striving to become a global leader in innovation," said William Hu, Managing Partner of Qiming Venture Partners. "The closing of our new funds will enable us to support more visionary founders realizing their entrepreneurial dreams."

    About Qiming Venture Partners

    Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

    Currently Qiming Venture Partners manages nine US Dollar funds and six RMB funds with $5.9 billion in assets under management. Since our establishment, we have invested in outstanding companies in the TMT and healthcare industries at the early and growth stages.

    Since our debut, we have backed over 380 fast-growing and innovative companies. Over 130 companies are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange and Shenzhen Stock Exchange, or achieved exit through M&A and other means. There are also over 40 portfolio companies that have achieved unicorn status.

    Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688))), Venus MedTech (SEHK:2500), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), WeDoctor Group, and UBTech among many others.

    Cision View original content:http://www.prnewswire.com/news-releases/qiming-venture-partners-closes-rmb-fund-vi-at-rmb-2-852-billion-301214577.html

    SOURCE Qiming Venture Partners

    View Full Article Hide Full Article
View All Schrodinger Inc. News